drugset / Trial / NCT00773344
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose(s) of this study is to determine the highest tolerated dose of tanespimycin and to determine anti-tumor activity (via objective response rate) of tanespimycin in patients with breast cancer who have not previously responded to Herceptin
Timeline
- Start
- 2005-12
- Primary completion
- 2009-05
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tanespimycin | Unknown | 225 mg/m2 | Intravenous |
| Subject | tanespimycin | Unknown | 300 mg/m2 | Intravenous |
| Subject | tanespimycin | Unknown | 375 mg/m2 | Intravenous |
| Subject | tanespimycin | Unknown | 400 mg/m2 | Intravenous |